Litigation Details for AMNEAL PHARMACEUTICALS LLC v. SANDOZ INC. (D.N.J. 2025)

AMNEAL PHARMACEUTICALS LLC v. SANDOZ INC. (D.N.J. 2025)

Docket		Date Filed	2025-01-07
Court	District Court, D. New Jersey	Date Terminated
Cause	15:1126 Patent Infringement	Assigned To	Georgette Castner
Jury Demand	None	Referred To	Tonianne J. Bongiovanni
Parties	SANDOZ INC.
Patents	10,098,845; 10,292,935; 10,688,058; 10,973,769; 10,987,313; 11,357,733; 11,622,941; 11,666,538; 11,986,449; 12,064,521; 12,109,185; 12,128,141
Attorneys	REBEKAH R. CONROY
Firms	Stone Conroy LLC
Link to Docket	External link to docket

Details for AMNEAL PHARMACEUTICALS LLC v. SANDOZ INC. (D.N.J. 2025)

Date Filed	Document No.	Description	Snippet	Link To Document
2025-01-07				External link to document

Litigation summary and analysis: Amneal Pharmaceuticals LLC v. Sandoz Inc. (3:25-cv-00181)

Last updated: June 24, 2026

Executive summary

• Case: Amneal Pharmaceuticals LLC v. Sandoz Inc., No. 3:25-cv-00181 (filed 2025, federal district court).
• Core posture: A Hatch-Waxman patent infringement dispute initiated by Amneal against Sandoz, aligned to an ANDA-based generic entry risk.
• What matters commercially: The decision on infringement and invalidity (or stipulations tied to effective dates) will determine whether Sandoz can launch on the ANDA timeline and whether Amneal’s asserted IP estate blocks that launch in whole or in part.

Because the user request does not specify (i) the drug/ANDA, (ii) the court docket details (complaint, patents-in-suit, asserted claims, Paragraph IV theory, scheduling order), or (iii) any public orders (e.g., TRO/PI rulings, claim constructions, stipulations, settlements), a complete and accurate litigation summary cannot be produced.